How the Lung-MAP Clinical Trial is Responding to Rapidly Changing Science

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

When the Lung Master Protocol clinical trial (Lung-MAP or S1400) (1) was launched in June 2014, the goal of this first-of-its kind trial was simple: find effective treatments for seriously ill patients suffering from a specific type of lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Roy S. Herbst
Co-principal investigator, Lung-MAP trial
Chief of Medical Oncology, associate director for translational research, Yale Cancer Center
David Gandara
Co-principal investigator, Lung-MAP trial; Director, Thoracic Oncology Program, University of California, Davis
Vassiliki Papadimitrakopoulou
Co-principal investigator, member of oversight and drug selection committees, Lung-MAP trial; professor, Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

Roy S. Herbst
Co-principal investigator, Lung-MAP trial
Chief of Medical Oncology, associate director for translational research, Yale Cancer Center
David Gandara
Co-principal investigator, Lung-MAP trial; Director, Thoracic Oncology Program, University of California, Davis
Vassiliki Papadimitrakopoulou
Co-principal investigator, member of oversight and drug selection committees, Lung-MAP trial; professor, Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login